L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 Ak,O,S,N,CH2,NH

G2 CH,N

G3 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 08:59:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4829 TO ITERATE

41.4% PROCESSED 2000 ITERATIONS 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 92413 TO 100747
PROJECTED ANSWERS: 33 TO 449

L2 5 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 08:59:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 95942 TO ITERATE

100.0% PROCESSED 95942 ITERATIONS 356 ANSWERS
SEARCH TIME: 00.00.02

L3 356 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'CAPLUS' ENTERED AT 08:59:26 ON 04 AUG 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Aug 2006 VOL 145 ISS 6
FILE LAST UPDATED: 2 Aug 2006 (20060802/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 19 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:104528 CAPLUS
DOCUMENT NUMBER: 144:192275
TITLE: Preparation of quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
INVENTOR(S): Rudolph, Joachim; O'Connor, Stephen; Coish, Philip; Wickens, Philip; Bondar, Georgiy; Chuang, Chih-Yuan; Ramsden, Philip; Lowe, Derek; Bierer, Donald; Chen, Libing; Fu, Wenlang; Khire, Uday; Liu, Xiao-Gao; Mcclure, Andrea; Wang, Lei; Yi, Lin; Esler, William
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 559 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012577	A2	20060202	WO 2005-US26192	20050722

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-590804P P 20040722

OTHER SOURCE(S): MARPAT 144:192275
GI

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB The invention is related to substituted quinazolinone derivs. I [R1 = (un)substituted pyrrolidin-3-yl, piperidin-3-yl, morpholin-4-yl, etc.; R2 = H, (un)substituted cyclo/alkyl, pyridinyl, Ph, etc.; R3 = H, halo, haloalkyl, (un)substituted Ph, alkyl, etc.; L = a bond, O, CO, S, SO2, NHSO2, NH and derivs., etc.; X = (CH2)m; m = 0-2; Y = (CH2)n; n = 1-2; p = 0-2; with provisos], and their pharmaceutically acceptable salts, and their compns., and methods for treating diabetes, obesity and related disorders, and regulation of glucose homeostasis and food intake (e.g., stimulation and suppression) (no data). The invention is also related to the preparation of quinazolinones I. Five biol. tests are given (no data).

Thus, II•TFA was prepared by amination of 5-fluoro-2-nitrobenzoic acid with N-methylbutylamine, reduction of the nitro compound, cyclocondensation with o-anisoyl chloride, reaction with tert-Bu 3-(aminomethyl)piperidine-1-carboxylate (intermediate not isolated), and Boc-deprotection in the presence of TFA.

IT 875259-38-4P, 6-(4-Chlorophenyl)-2-cyclobutyl-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of quinazolinones useful for regulation of glucose homeostasis and food intake)

RN 875259-38-4 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-cyclobutyl-3-(3-piperidinylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 875258-90-5P, 2-Cyclopropyl-6-(4-fluorophenoxy)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-30-6P, 6-(4-Chlorophenyl)-2-cyclopropyl-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-31-7P, 6-(4-Chlorophenyl)-2-cyclopropyl-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875259-39-5P, 6-(4-Chlorophenyl)-2-cyclobutyl-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875263-42-6P, 3-[[6-(4-Chlorophenyl)-2-cyclopentyl-4-oxoquinazolin-3(4H)-yl]methyl]-1-ethylpiperidinium trifluoroacetate 875265-37-5P, (S)-6-[3-Chloro-4-(trifluoromethyl)phenyl]-2-cyclopropyl-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875265-38-6P, (S)-6-(2-Chlorophenyl)-2-cyclopropyl-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875266-27-6P, 2-Cyclopropyl-6-(4-fluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875266-28-7P, 2-Cyclopropyl-6-(2,4-difluorophenyl)-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one 875266-31-2P, 6-(4-Chlorophenyl)-2-cyclopentyl-3-[(piperidin-3-yl)methyl]quinazolin-4(3H)-one 875266-32-3P, 6-(4-Chlorophenyl)-2-cyclopentyl-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazolinones useful for regulation of glucose homeostasis and food intake)

RN 875258-90-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-cyclopropyl-6-(4-fluorophenoxy)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 875259-30-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-cyclopropyl-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875259-31-7 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-cyclopropyl-3-(3-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 875259-39-5 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-cyclobutyl-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 875263-42-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-cyclopentyl-3-[(1-ethyl-3-piperidinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 875263-41-5
CMF C27 H32 Cl N3 O



CM 2

CRN 76-05-1

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C2 H F3 O2

RN 875265-37-5 CAPLUS
CN 4(3H)-Quinazolinone, 6-[3-chloro-4-(trifluoromethyl)phenyl]-2-cyclopropyl-3-[[(3S)-1-(1-methylethyl)-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875265-38-6 CAPLUS
CN 4(3H)-Quinazolinone, 6-(2-chlorophenyl)-2-cyclopropyl-3-[[(3S)-1-(1-methylethyl)-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 875266-27-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-cyclopropyl-6-(4-fluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4(3H)-Quinazolinone, 6-bromo-2-cyclopropyl-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875266-28-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-cyclopropyl-6-(2,4-difluorophenyl)-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 875266-31-2 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-cyclopentyl-3-(3-piperidinylmethyl)- (9CI) (CA INDEX NAME)



RN 875266-32-3 CAPLUS
CN 4(3H)-Quinazolinone, 6-(4-chlorophenyl)-2-cyclopentyl-3-[[1-(1-methylethyl)-3-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



IT 875269-80-0P, 6-Bromo-2-cyclopropyl-3-[(1-isopropylpiperidin-3-yl)methyl]quinazolin-4(3H)-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazolinones useful for regulation of glucose homeostasis and food intake)
RN 875269-80-0 CAPLUS

L4 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1240775 CAPLUS
DOCUMENT NUMBER: 144:17202
TITLE: Novel 2-amino-4-quinazolinones and 2-amino-4-oxoquinazolones as LXR (liver X receptor) nuclear receptor binding compounds with partial agonistic properties
INVENTOR(S): Deuschle, Ulrich; Loebbert, Ralph; Blume, Beatrix; Koegl, Manfred; Kremoser, Claus; Kober, Ingo; Bauer, Ulrike; Hermann, Kristina; Albers, Michael
PATENT ASSIGNEE(S): Germany
SOURCE: U.S. Pat. Appl. Publ., 52 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005261319	A1	20051124	US 2005-76163	20050309
EP 1407774	A1	20040414	EP 2002-20255	20020910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CA 2498655	AA	20040325	CA 2003-2498655	20030702
WO 2004024162	A1	20040325	WO 2003-EP7067	20030702
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003296861	A1	20040430	AU 2003-296861	20030702
JP 2006502169	T2	20060119	JP 2004-535046	20030702
WO 2004024161	A1	20040325	WO 2003-EP10036	20030910
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003271595	A1	20040430	AU 2003-271595	20030910
EP 1536799	A1	20050608	EP 2003-753402	20030910
EP 1536799	B1	20060510		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

EP 2002-20255	A	20020910
WO 2003-EP7067	A2	20030702
WO 2003-EP10036	A2	20030910

L4 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 144:17202
GI



I

AB The present invention relates to compds. according to the general formula (I) wherein R1, R2, R3 and/or R4, are independently from each other selected from H, halogen, hydroxy, protected hydroxy, cyano, nitro, C1 to C6 alkyl, C1 to C6 substituted alkyl, C1 to C7 alkoxy, C1 to C7 substituted alkoxy, C1 to C7 acyl, C1 to C7 substituted acyl, C1 to C7 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, carboxamide, protected carboxamide, N-(C1 to C6 alkyl)carboxamide, protected N-(C1 to C6 alkyl)carboxamide, N,N-di(C1 to C6 alkyl)carboxamide, trifluoromethyl, N-[(C1 to C6 alkyl)sulfonyl]amino, N-(phenylsulfonyl)amino or substituted or unsubstituted phenyl; R5 is H, C1 to C8 alkyl, C1 to C8 substituted alkyl, C7 to C12 alkylphenyl or C7 to C12 substituted phenylalkyl, R6 is H, C1 to C8 alkyl, C1 to C8 substituted alkyl, C7 to C12 alkylphenyl or C7 to C12 substituted phenylalkyl, R7 is H, C1 to C8 alkyl, C1 to C8 substituted alkyl, C7 to C12 alkylphenyl or C7 to C12 substituted phenylalkyl, and R6 and R7 may be taken together with nitrogen to form a heterocycle or substituted heterocycle or a heteroaryl or substituted heteroaryl ring. I bind to the LXR receptors and act as agonists and antagonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compds. and the production of medicaments using said compds.

IT 671211-38-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel 2-aminoquinazolinones and 2-aminooxoquinazolones as LXR nuclear receptor binding compds. with partial agonistic properties for treatment of diseases)

RN 671211-38-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3,4-dihydro-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:490293 CAPLUS
DOCUMENT NUMBER: 143:43903
TITLE: Preparation of piperazinylguanidinoquinazolinones as melanocortin-4 receptor (MCR-4) agonists with reduced bioaccumulation
INVENTOR(S): Boyce, Rustum S.; Speake, Jason D.; Phillips, James
PATENT ASSIGNEE(S): Chiron Corporation, USA; Glaxosmithkline
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051391	A1	20050609	WO 2004-US39020	20041119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004293012	A1	20050609	AU 2004-293012	20041119
US 2005192297	A1	20050901	US 2004-993147	20041119
PRIORITY APPLN. INFO.:			US 2003-523336P P	20031119
			US 2003-524492P P	20031124
			WO 2004-US39020 W	20041119

OTHER SOURCE(S): MARPAT 143:43903
GI

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title compds. [I; R1 = (substituted) aralkyl, heteroarylalkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkyl; R2 = H, (substituted) aralkyl, heteroarylalkyl, alkoxy, alkylamino, dialkylamino, aryl, heteroaryl, heterocyclyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkyl; R3, R4, R6 = H, Cl, F, Br, iodo, OH, NH2, cyano, NO2, (substituted) alkoxy, alkyl; R31 = H, (substituted) alkyl, aryl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocyclyl, heterocyclylalkyl, aralkyl, heteroarylalkyl, cycloalkylalkyl; Z = (substituted) 3-oxopiperazinyl; and tautomers], were prepared Thus, title compound (II) (preparation via coupling of 6-methylpiperazin-2-one with the corresponding quinazolinylthiourea derivative in the presence of polymer-supported carbodiimide) showed a plasma half life of 1.9 h in mice.

IT 629628-69-9P 817626-63-4P 817627-21-7P
817627-22-8P 817627-28-4P 817627-29-5P
817627-30-8P 817627-35-3P 817627-36-4P
817627-41-1P 817627-42-2P 817627-43-3P
817627-44-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperazinylguanidinoquinazolinones as melanocortin-4 receptor (MCR-4) agonists with reduced bioaccumulation)

RN 629628-69-9 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(4-fluorophenyl)ethyl]-3,4-dihydro-2-(4-methylcyclohexyl)-4-oxo-7-quinazolinyl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817626-63-4 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-4-oxo-7-quinazolinyl]-3-methyl-5-oxo-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-21-7 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(3-hydroxy-1-azetidinyl)-4-oxo-7-quinazolinyl]-3-methyl-5-oxo-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817627-29-5 CAPLUS
CN 4-Morpholinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(4-hydroxy-1-piperidinyl)-4-oxo-7-quinazolinyl]-2,6-dimethyl-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (2R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-30-8 CAPLUS
CN 4-Morpholinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(4-hydroxy-1-piperidinyl)-4-oxo-7-quinazolinyl]-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817627-22-8 CAPLUS
CN 1-Azetidinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(3-hydroxy-1-azetidinyl)-4-oxo-7-quinazolinyl]-3-hydroxy-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-28-4 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(4-hydroxy-1-piperidinyl)-4-oxo-7-quinazolinyl]-3-methyl-5-oxo-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817627-35-3 CAPLUS
CN 1-Azetidinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(4-hydroxy-1-piperidinyl)-4-oxo-7-quinazolinyl]-3-hydroxy-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-36-4 CAPLUS
CN 1-Piperazinecarboximidamide, 4-cyano-N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(4-hydroxy-1-piperidinyl)-4-oxo-7-quinazolinyl]-3,5-dimethyl-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817627-41-1 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-2-(4,4-difluoro-1-piperidinyl)-3,4-dihydro-4-oxo-7-quinazolinyl]-3-methyl-5-oxo-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-42-2 CAPLUS
CN 1-Azetidinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-2-(4,4-difluoro-1-piperidinyl)-3,4-dihydro-4-oxo-7-quinazolinyl]-3-hydroxy-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817627-43-3 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-[4-(hydroxymethyl)-1-piperidinyl]-4-oxo-7-quinazolinyl]-3-methyl-5-oxo-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-44-4 CAPLUS
CN 1-Azetidinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-[4-(hydroxymethyl)-1-piperidinyl]-4-oxo-7-quinazolinyl]-3-hydroxy-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:460917 CAPLUS
DOCUMENT NUMBER: 143:153336
TITLE: Single step synthesis of 2,3-dialkyl-6-nitro-quinazolin-4(3H)-imines and 3,5-dialkyl-9-nitro-imidazo[1,2-c]quinazolin-2(3H)-ones
AUTHOR(S): Erba, Emanuela; Pocar, Donato; Trimarco, Pasqualina
CORPORATE SOURCE: Istituto di Chimica Organica Alessandro Marchesini' e Centro Interuniversitario di Ricerca sulle Reazioni Pericicliche e Sintesi di Sistemi Etero- e Carbociclici, Universita degli Studi di Milano, Milan, I-20133, Italy
SOURCE: Tetrahedron (2005), 61(24), 5778-5781
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:153336

AB A single step synthesis of 2,3-dialkyl-6-nitro-quinazolin-4(3H)-imines and 3,5-dialkyl-9-nitro-imidazo-[1,2-c]-quinazolin-2(3H)-ones from simple carbonyl compds., primary amines or amino acid Me esters and 2-azido-5-nitro-benzonitrile was developed. Key intermediates were N,N'-disubstituted amidines obtained by rearrangement of 4,5-dihydrotriazoles; the new heterocyclic rings were formed by spontaneous intramol. reaction of the amino and cyano groups which are present in the intermediates.

IT 859497-76-0P 859497-77-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of 2,3-dialkyl-6-nitro-quinazolin-4(3H)-imines and 3,5-dialkyl-9-nitro-imidazo[1,2-c]quinazolin-2(3H)-ones from carbonyl compds., primary amines or amino acid Me esters and 2-azido-5-nitro-benzonitrile)

RN 859497-76-0 CAPLUS
CN 4(3H)-Quinazolinimine, 2-cyclopentyl-6-nitro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 859497-77-1 CAPLUS
CN 4(3H)-Quinazolinimine, 2-cyclohexyl-6-nitro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:85958 CAPLUS
DOCUMENT NUMBER: 142:336323
TITLE: Microwave-assisted one-pot synthesis of 2,3-disubstituted 3H-quinazolin-4-ones
AUTHOR(S): Liu, Ji-Feng; Lee, Jaekyoo; Dalton, Audra M.; Bi, Grace; Yu, Libing; Baldino, Carmen M.; McElory, Eric; Brown, Matt
CORPORATE SOURCE: Division of Chemical Technologies, ArQule, Inc., Woburn, MA, 01801, USA
SOURCE: Tetrahedron Letters (2005), 46(8), 1241-1244
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:336323

AB A practical synthesis of 2,3-disubstituted 3H-quinazolin-4-ones with broad chemical scope is described. The key step is the microwave promoted one-pot, two-step reaction sequence combining anthranilic acids, carboxylic acids, and amines providing efficient access to this important class of heterocycles. Furthermore, the reaction of 2-amino-3-pyridinecarboxylic acid with benzoyl chloride and benzenemethanamine gave 2-phenyl-3-(phenylmethyl)pyrido[2,3-d]pyrimidin-4(3H)-one.

IT 40057-11-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (cyclopropyl)[(phenyl)ethyl]-4(3H)-quinazolinone by microwave-assisted reaction using (amino)benzoic acid, benzoyl chloride, and amine as starting materials)

RN 40057-11-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-cyclopropyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1156498 CAPLUS
DOCUMENT NUMBER: 142:93848
TITLE: Preparation of guanidino-substituted quinazolinone compounds as MC4-R agonists
INVENTOR(S): Boyce, Rustum S.; Aurrecoechea, Natalia; Chu, Daniel; Smith, Aaron; Conlee, Christopher R.; Thompson, Brian D.; De Armas, Kuntz Judith; Musso, David L.; Barvian, Kevin K.; Thomson, Stephen A.; Swain, William R.; Du, Kien S.; Chauder, Brian A.; Speake, Jason D.; Bishop, Michael J.
PATENT ASSIGNEE(S): Chiron Corporation, USA; Glaxosmithkline
SOURCE: PCT Int. Appl., 277 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112793	A1	20041229	WO 2004-US15959	20040521
WO 2004112793	B1	20050310		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249120	A1	20041229	AU 2004-249120	20040521
CA 2523015	AA	20041229	CA 2004-2523015	20040521
US 2005059662	A1	20050317	US 2004-850967	20040521
EP 1651229	A1	20060503	EP 2004-776069	20040521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-473317P P 20030523
US 2003-523336P P 20031119
US 2003-524492P P 20031124
WO 2004-US15959 W 20040521

OTHER SOURCE(S): MARPAT 142:93848
GI

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB A variety of small mol., guanidine-containing mols. capable of acting as MC4-R agonists such as I-III (Z1 = CR4, N; Z2 = CR5, N; Z3 = CR6, N; R1 = (un)substituted arylalkyl, heteroarylalkyl, aryl, heteroaryl, etc.; R2 = H, alkyl, aryl, etc.; R3 = H, arylalkyl, aryl, etc.; R4-R6 = H, Cl, I, F, Br, OH, etc.; W = IV (wherein R11, R12 = H, (un)substituted alkyl, aryl, etc.; at least one of R11 and R12 is (un)substituted heterocyclylalkyl; R13 = H, (un)substituted aryl, alkyl, etc.; R14 = H, (un)substituted alkyl, cycloalkyl, etc.)] are provided. General procedures used in the synthesis of compds. I-III are described. E.g., a multi-step synthesis of (1S,2S,3S,5R)-V, was given. The exemplified compds. I-III were tested against MC4-R and exhibited -logEC50 values above about 3. The compds. I are useful in treating MC4-R mediated diseases such as obesity and type II diabetes. The pharmaceutical composition comprising the compound I is disclosed.

IT 629628-69-9P 817626-63-4P 817627-21-7P
817627-22-8P 817627-28-4P 817627-29-5P
817627-30-8P 817627-35-3P 817627-36-4P
817627-41-1P 817627-42-2P 817627-43-3P
817627-44-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of guanidino-substituted quinazolinone compds. as MC4-R agonists)

RN 629628-69-9 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(4-fluorophenyl)ethyl]-3,4-dihydro-2-(4-methylcyclohexyl)-4-oxo-7-quinazolinyl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817626-63-4 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-[(3S)-3-hydroxy-1-pyrrolidinyl]-4-oxo-7-quinazolinyl]-3-methyl-5-oxo-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-21-7 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(3-hydroxy-1-azetidinyl)-4-oxo-7-quinazolinyl]-3-methyl-5-oxo-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817627-29-5 CAPLUS
CN 4-Morpholinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(4-hydroxy-1-piperidinyl)-4-oxo-7-quinazolinyl]-2,6-dimethyl-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (2R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-30-8 CAPLUS
CN 4-Morpholinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(4-hydroxy-1-piperidinyl)-4-oxo-7-quinazolinyl]-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817627-22-8 CAPLUS
CN 1-Azetidinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(3-hydroxy-1-azetidinyl)-4-oxo-7-quinazolinyl]-3-hydroxy-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-28-4 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(4-hydroxy-1-piperidinyl)-4-oxo-7-quinazolinyl]-3-methyl-5-oxo-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817627-35-3 CAPLUS
CN 1-Azetidinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(4-hydroxy-1-piperidinyl)-4-oxo-7-quinazolinyl]-3-hydroxy-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-36-4 CAPLUS
CN 1-Piperazinecarboximidamide, 4-cyano-N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-(4-hydroxy-1-piperidinyl)-4-oxo-7-quinazolinyl]-3,5-dimethyl-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3R,5S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817627-41-1 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-2-(4,4-difluoro-1-piperidinyl)-3,4-dihydro-4-oxo-7-quinazolinyl]-3-methyl-5-oxo-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-42-2 CAPLUS
CN 1-Azetidinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-2-(4,4-difluoro-1-piperidinyl)-3,4-dihydro-4-oxo-7-quinazolinyl]-3-hydroxy-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 817627-43-3 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-[4-(hydroxymethyl)-1-piperidinyl]-4-oxo-7-quinazolinyl]-3-methyl-5-oxo-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 817627-44-4 CAPLUS
CN 1-Azetidinecarboximidamide, N-[3-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2-[4-(hydroxymethyl)-1-piperidinyl]-4-oxo-7-quinazolinyl]-3-hydroxy-N'-[(1R,2S,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1125357 CAPLUS
DOCUMENT NUMBER: 142:82382
TITLE: Pyrimidine compound and optical recording material using it
INVENTOR(S): Shiozaki, Hiroyoshi; Ishida, Tsutomu; Ogiso, Akira
PATENT ASSIGNEE(S): Mitsui Chemicals Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 45 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004358819	A2	20041224	JP 2003-160251	20030605
PRIORITY APPLN. INFO.:			JP 2003-160251	20030605

OTHER SOURCE(S): MARPAT 142:82382
GI



AB A compound I [AR1-3 = (un)substituted aromatic residue; X11-12 = O, S; R11-12 = H, (un)substituted alkyl, aralkyl, aryl] having two 2-[4-(thi)oxopyrimidinyl]-1,3-propanedione structures is claimed. The material contains ≥1 of I. The material is recorded and read by 300-900 nm laser beam, especially by blue-violet laser with 400-410 nm.

IT 811803-68-6
RL: TEM (Technical or engineered material use); USES (Uses)
(optical recording material containing pyrimidinyl propanedione compound)

RN 811803-68-6 CAPLUS
CN s-Indacene-1,3,5,7(2H,6H)-tetrone, 2,6-bis[3,4-dihydro-6-(4-morpholinyl)-4-oxo-3-(phenylmethyl)-2-quinazolinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:857326 CAPLUS
DOCUMENT NUMBER: 141:309639
TITLE: Dipeptidyl peptidase inhibitors
INVENTOR(S): Feng, Jun; Gwaltney, Stephen L.; Kaldor, Stephen W.; Stafford, Jeffrey A.; Wallace, Michael B.; Zhang, Zhiyuan
PATENT ASSIGNEE(S): Syrrx, Inc., USA
SOURCE: PCT Int. Appl., 244 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087053	A2	20041014	WO 2004-US9217	20040324
WO 2004087053	C2	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2518465	AA	20041014	CA 2004-2518465	20040324
US 2004242568	A1	20041202	US 2004-809636	20040324
US 2004242566	A1	20041202	US 2004-809638	20040324
US 2004259870	A1	20041223	US 2004-809637	20040324
US 2005004117	A1	20050106	US 2004-809635	20040324
EP 1608317	A2	20051228	EP 2004-758366	20040324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-457785P P 20030325
WO 2004-US9217 W 20040324

OTHER SOURCE(S): MARPAT 141:309639
GI



AB Dipeptidyl peptidase IV inhibitors I [Q = CO, SO, SO2, C:NR5; R1 = ZR6; Z = moiety providing 1-6 atom separation between R6 and ring; R2 = (substituted)3-7-membered ring; R3,R4 = taken together form a (substituted)5-6-membered ring; R5 = H, (substituted)alkyl, cycloalkyl, etc.; R6 = (substituted)C3-7-cycloalkyl or aryl] are disclosed. Thus, 2-[2-(3-aminopiperidin-1-yl)-6,7-dimethoxy-4-oxo-4H-quinazolin-3-ylmethyl]benzonitrile (I; R1 = 2-cyanophenylmethyl; R2 = 3-aminopiperidin-1-yl; R3,R4 = dimethoxyphenyl) was synthesized. This compd. exhibited enhanced stability in rat liver microsomes.

IT 769157-54-2P 769157-55-3P 769157-56-4P
769157-57-5P 769157-58-6P 769157-59-7P
769157-63-3P 769157-65-5P 769157-71-3P
769157-81-5P 769157-89-3P 769157-91-7P
769157-92-8P 769157-93-9P 769157-94-0P
769157-95-1P 769158-01-2P 769158-02-3P
769158-03-4P 769158-04-5P 769158-05-6P
769158-06-7P 769158-14-7P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(dipeptidyl peptidase inhibitors)

RN 769157-54-2 CAPLUS
CN Benzonitrile, 2-[[2-(3-amino-1-piperidinyl)-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 769157-55-3 CAPLUS
CN Benzonitrile, 2-[[2-(3-amino-1-piperidinyl)-6,7-dimethoxy-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 769157-56-4 CAPLUS
CN Benzonitrile, 2-[[2-(3-amino-1-piperidinyl)-8-methoxy-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 769157-57-5 CAPLUS
CN Benzonitrile, 2-[[2-(3-amino-1-piperidinyl)-7-chloro-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 769157-58-6 CAPLUS
CN Benzonitrile, 2-[[2-(3-amino-1-piperidinyl)-8-chloro-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 769157-59-7 CAPLUS
CN Benzonitrile, 2-[[2-(3-amino-1-piperidinyl)-6-fluoro-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 769157-63-3 CAPLUS
CN Benzonitrile, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6-chloro-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769157-65-5 CAPLUS
CN Benzonitrile, 2-[[2-[(3R)-3-amino-1-piperidinyl]-7-fluoro-6-methoxy-4-oxo-3(4H)-quinazolinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 769157-64-4
CMF C22 H22 F N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 769157-89-3 CAPLUS
CN Benzonitrile, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6-bromo-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769157-91-7 CAPLUS
CN Benzonitrile, 2-[[2-[(3R)-3-amino-1-pyrrolidinyl]-6-bromo-4-oxo-3(4H)-quinazolinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 769157-90-6
CMF C20 H18 Br N5 O

Absolute stereochemistry.

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 769157-71-3 CAPLUS
CN Benzonitrile, 2-[[2-[(3R)-3-amino-1-piperidinyl]-5-fluoro-4-oxo-3(4H)-quinazolinyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 769157-70-2
CMF C21 H20 F N5 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 769157-81-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(3R)-3-amino-1-piperidinyl]-6-fluoro-3-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 769157-92-8 CAPLUS
CN Benzonitrile, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6,8-dichloro-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769157-93-9 CAPLUS
CN Benzonitrile, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6-methoxy-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 769157-94-0 CAPLUS
CN Benzamide, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769157-95-1 CAPLUS
CN Benzonitrile, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6-fluoro-7-(4-morpholinyl)-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 769158-01-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-(3-amino-1-piperidinyl)-6,7-dimethoxy-3-[(2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 769158-02-3 CAPLUS
CN Benzoic acid, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6,7-dimethoxy-4-oxo-3(4H)-quinazolinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769158-03-4 CAPLUS

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769158-04-5 CAPLUS
CN Benzoic acid, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6,7-dimethoxy-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 769158-05-6 CAPLUS
CN Benzoic acid, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 769158-06-7 CAPLUS
CN Benzonitrile, 2-[[6,7-dimethoxy-4-oxo-2-(1-piperidinyl)-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 769158-14-7 CAPLUS
CN Benzonitrile, 2-[[2-[(3R)-3-amino-1-piperidinyl]-6-fluoro-4-oxo-3(4H)-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:211993 CAPLUS
DOCUMENT NUMBER: 140:264510
TITLE: 4-Oxo-quinazoline agonist ligands for the liver X nuclear receptor and their use in treatment of disorders of lipid metabolism
INVENTOR(S): Kober, Ingo; Albers, Michael; Koegl, Manfred; Blume, Beatrix; Deuschle, Ulrich; Kremoser, Claus
PATENT ASSIGNEE(S): Phenex Pharmaceuticals A.-G., Germany
SOURCE: Eur. Pat. Appl., 85 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1398032	A1	20040317	EP 2003-20417	20030910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
EP 1407774	A1	20040414	EP 2002-20255	20020910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			EP 2002-20255	A 20020910

OTHER SOURCE(S): MARPAT 140:264510
AB 4-Oxo-quinazoline ligands for liver X receptors (LXR receptors, LXRα/NR1 H3 and LXRbeta/NR1H2) acting as selective agonists of the receptor are described. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptors and selective agonistic effects by said compds. and the production of medicaments using said compds. In particular the compds. are useful in the treatment of hypercholesteremia, obesity or other diseases associated with elevated lipoprotein (LDL) levels. Reporter gene methods of screening for effective agonists of the receptor are described.
IT 671211-38-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as liver X receptor agonist; 4-oxo-quinazoline agonist ligands for liver X nuclear receptor and their use in treatment of disorders of lipid metabolism)
RN 671211-38-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3,4-dihydro-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:951025 CAPLUS
DOCUMENT NUMBER: 140:16739
TITLE: Preparation of (guanidino)quinazolinones as MC4-R agonists for treatment of obesity and type II diabetes
INVENTOR(S): Boyce, Rustum S.; Aurrecoechea, Natalia; Chu, Daniel; Smith, Aaron
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 170 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003099818	A1	20031204	WO 2003-US16442	20030523
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2486966	AA	20031204	CA 2003-2486966	20030523
AU 2003245325	A1	20031212	AU 2003-245325	20030523
US 2004019049	A1	20040129	US 2003-444495	20030523
US 7034033	B2	20060425		
EP 1551834	A1	20050713	EP 2003-738964	20030523
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005531583	T2	20051020	JP 2004-507475	20030523
US 2006030573	A1	20060209	US 2005-248040	20051011
PRIORITY APPLN. INFO.:			US 2002-382762P	P 20020523
			US 2003-441019P	P 20030117
			US 2003-444495	A3 20030523
			WO 2003-US16442	W 20030523

OTHER SOURCE(S): MARPAT 140:16739
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title low mol. weight, guanidine-containing mols. I, II, and III [wherein Z1 = CR4, N; Z2 = CR5, N; Z3 = CR6, N; R1 = (un)substituted (hetero)arylalkyl, (hetero)aryl, heterocyclyl, cycloalkyl(alkyl), heterocycloalkyl(alkyl), alkenyl, alkynyl, alkyl; R2 = H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, heteroaryl, heterocyclyl, (hetero)arylalkyl, cycloalkylalkyl, alkylcarbonyl, arylcarbonyl; R3 = H or (un)substituted (hetero)arylalkyl, alkoxy, (di)alkylamino, (hetero)aryl, heterocyclyl, (hetero)cycloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkyl; R4-R6 = independently H, halo, OH, NH2, CN, NO2, or (un)substituted alkoxy, (cyclo)alkyl, alkenyl, alkynyl, (di)alkylamino, heterocycylamino(carbonyl), heteroarylamino(carbonyl), aminocarbonyl, (di)alkylaminocarbonyl; W = (un)substituted guanidino; and prodrugs, pharmaceutically acceptable salts, stereoisomers, tautomers, hydrates, hydrides, or solvates thereof] were prepd. as melanocortin-4 receptor (MC4-R) agonists. For example, amidation of 4,5-difluoroanthranilic acid with 4-fluorophenylethylamine in the presence of HOBt and diisopropylethylamine in THF provided the benzamide (90%). The 2-aminobenzamide was cyclized with tri-Me orthoformate by heating to 120° for 3 h affording 6,7-difluoro-3-[2-(4-fluorophenyl)ethyl]-3-hydroquinazolin-4-one (75%), which was converted to the azide (95%) by reaction with NaN3 in DMSO. The azide was coupled with (1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-ylisocyanate in the presence of PMe3 in THF, and the product was reacted with (6S,2R)-2,6-dimethylpiperazine to give the guanidine deriv. IV. EC50 values of one hundred five test compds. were detd. by treating cells expressing MC4-R with test compds., lysing the cells, and measuring intercellular cAMP concns. Compds. listed displayed -log EC50 values above about 3. Thus, I, II, III, and their pharmaceutical compns. are useful for the treatment of MC4-R-mediated diseases, such as obesity or type II diabetes (no data).
IT 629628-69-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MC4-R agonist; preparation of (guanidino)quinazolinones as MC4-R agonists for treatment of obesity and type II diabetes)
RN 629628-69-9 CAPLUS
CN 1-Piperazinecarboximidamide, N-[3-[2-(4-fluorophenyl)ethyl]-3,4-dihydro-2-(4-methylcyclohexyl)-4-oxo-7-quinazolinyl]-3-methyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:335019 CAPLUS
DOCUMENT NUMBER: 138:346575
TITLE: Imide compounds and their application in optical recording media
INVENTOR(S): Ogiso, Akira; Shiozaki, Hiroyoshi; Ishida, Tsutomu; Tsukahara, Hisashi; Misawa, Tsutami; Inoue, Koji; Koike, Tadashi; Ueno, Keiji; Inatomi, Yuji; Nara, Ryousuke
PATENT ASSIGNEE(S): Mitsui Chemicals, Inc., Japan
SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035407	A1	20030501	WO 2002-JP10939	20021022
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1445115	A1	20040811	EP 2002-777915	20021022
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
CN 1575236	A	20050202	CN 2002-820890	20021022
JP 2004042596	A2	20040212	JP 2002-324789	20021108
US 2005208425	A1	20050922	US 2004-493034	20040419
PRIORITY APPLN. INFO.:			JP 2001-323900 A	20011022
			JP 2001-344742 A	20011109
			JP 2002-147538 A	20020522
			JP 2002-210949 A	20020719
			JP 2002-244776 A	20020826
			JP 2002-246872 A	20020827
			WO 2002-JP10939 W	20021022

OTHER SOURCE(S): MARPAT 138:346575
AB An optical recording medium contains in its recording layer at least one imide compound having a metallocene substitution group.
IT 516516-32-8 516517-60-5 516518-81-3
RL: MOA (Modifier or additive use); USES (Uses)
(metallocene-containing imide compds. optical recording media)

L4 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 516516-32-8 CAPLUS
CN Ferrocene,
[4-[7-[3,4-dihydro-4-oxo-3-(phenylmethyl)-6-(trifluoromethyl)-2-quinazolinyl]-3,6,7,8-tetrahydro-1,3,6,8-tetraoxoindeno[5,6-f]isoindol-2(1H)-yl]-3,5-dimethylphenyl]- (9CI) (CA INDEX NAME)



RN 516517-60-5 CAPLUS
CN Ferrocene,
[4-[6-[3,4-dihydro-4-oxo-3-(phenylmethyl)-6-(trifluoromethyl)-2-quinazolinyl]-3,5,6,7-tetrahydro-1,3,5,7-tetraoxocyclopent[f]isoindol-2(1H)-yl]-3,5-dimethylphenyl]- (9CI) (CA INDEX NAME)



RN 516518-81-3 CAPLUS
CN Ferrocene,
[4-[7-[3,4-dihydro-4-oxo-3-(phenylmethyl)-6-(trifluoromethyl)-2-quinazolinyl]-3,6,7,8-tetrahydro-1,3,6,8-tetraoxonaphth[2,1,8-def]isoquinolin-2(1H)-yl]-3,5-dimethylphenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:543605 CAPLUS
DOCUMENT NUMBER: 138:106649
TITLE: Solid-phase synthesis of quinazolin-4(3H)-ones with three-point diversity
AUTHOR(S): Kesarwani, A. P.; Srivastava, G. K.; Rastogi, S. K.; Kundu, B.
CORPORATE SOURCE: Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, 226 001, India
SOURCE: Tetrahedron Letters (2002), 43(32), 5579-5581
CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:106649
GI



I

AB A versatile method for the solid-phase synthesis of differentially substituted quinazolin-4(3H)-ones I (R1 = Et, Ph, PhCH2; R2 = Bu, R3 = Me; R2R3N = N-methylpiperazino, 4-benzylpiperidino, morpholino; R4 = R5 = H, R4R5 = CH:CHCH:CH) was developed using immobilized arylguanidines. The latter were obtained by treating the amino group of polymer-linked aminoaryl amide with isothiocyanates R1NCS followed by coupling of resulting thioureas with secondary amines R3NHR4. Under mild acidic conditions, these immobilized arylguanidines underwent cyclization/polymer matrix cleavage to give I in high yields and purities.
IT 485402-04-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase synthesis of (amino)quinazolinones with three points of diversity from aminoaryl carboxylic acids, isothiocyanates, and secondary amines)
RN 485402-04-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-(phenylmethyl)-2-[4-(phenylmethyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:247321 CAPLUS
DOCUMENT NUMBER: 134:280852
TITLE: Quinazolinones useful as glycoprotein IbIX antagonists, and their preparation and use for control of thrombotic disorders
INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany; et al.
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023365	A1	20010405	WO 2000-EP8940	20000913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385921	AA	20010405	CA 2000-2385921	20000913
BR 2000014294	A	20020521	BR 2000-14294	20000913
EP 1216235	A1	20020626	EP 2000-965991	20000913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 6890930	B1	20050510	US 2002-89166	20000913
NO 2002001502	A	20020326	NO 2002-1502	20020326
PRIORITY APPLN. INFO.:			US 1999-407958 A	19990928
			US 1999-287586P P	19990928
			WO 2000-EP8940 W	20000913

OTHER SOURCE(S): MARPAT 134:280852
GI

L4 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH2Ar, Hal, NH2, NHA, NA2, NO2, cyano, COR2, CONH2, CONHA, CONA2, CO2H, CO2A, SO2A; R2, R3 = H, A, C(:NH)NH2, solid phase; R4 = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C2-4 alkylene; Z = bond, phenylene; A = (un)branched C1-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)saturated mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n = 1-3; m = 0-3; with a variety of provisos]. The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, 3-(aminomethyl)benzylamine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R4YCHO, oxidation of the resultant dihydroquinazolinone ring system, and cleavage from the resin with CF3CO2H, gave a variety of compds. I, e.g., the preferred compound II.
IT 332362-66-0P, 3-(3-Aminomethylbenzyl)-6-chloro-2-cyclohexyl-3H-quinazolin-4-one 332362-67-1P, 3-(3-Aminomethylbenzyl)-6-methyl-2-cyclohexyl-3H-quinazolin-4-one 332362-68-2P, 3-(3-Aminomethylbenzyl)-7-chloro-2-cyclohexyl-3H-quinazolin-4-one 332362-69-3P, 3-(3-Aminomethylbenzyl)-6-methoxy-2-cyclohexyl-3H-quinazolin-4-one 332362-70-6P, 3-(3-Aminomethylbenzyl)-2-cyclohexyl-3H-quinazolin-4-one
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate)
RN 332362-66-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-6-chloro-2-cyclohexyl- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 332362-67-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-cyclohexyl-6-methyl- (9CI) (CA INDEX NAME)



RN 332362-68-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-7-chloro-2-cyclohexyl- (9CI) (CA INDEX NAME)



RN 332362-69-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-cyclohexyl-6-methoxy- (9CI) (CA INDEX NAME)



RN 332362-70-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)phenyl]methyl]-2-cyclohexyl- (9CI)

L4 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:247320 CAPLUS
DOCUMENT NUMBER: 134:280851
TITLE: Quinazolinones useful as glycoprotein IbIX antagonists, and their preparation and use for control of thrombotic disorders
INVENTOR(S): Mederski, Werner; Devant, Ralf; Barnickel, Gerhard; Bernotat-danielowski, Sabine; Melzer, Guido; Dhanoa, Daljit; Zhao, Bao-ping; Rinker, James; Player, Mark; Soll, Richard
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany; et al.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023364	A1	20010405	WO 2000-EP8939	20000913
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385918	AA	20010405	CA 2000-2385918	20000913
BR 2000014311	A	20020521	BR 2000-14311	20000913
EP 1216233	A1	20020626	EP 2000-962482	20000913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
NO 2002001503	A	20020326	NO 2002-1503	20020326
US 7060706	B1	20060613	US 2002-89167	20020829
PRIORITY APPLN. INFO.:			US 1999-407939 A	19990928
			US 1999-325777P P	19990928
			WO 2000-EP8939 W	20000913

OTHER SOURCE(S): MARPAT 134:280851
GI

L4 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Quinazolinones I and their pharmaceutically tolerable salts and solvates are disclosed [in which R, R1 = H, A, OH, OA, OCH2Ar, Hal, NH2, NHA, NA2, NO2, cyano, COR2, CONH2, CONHA, CONA2, CO2H, CO2A, SO2A; R2, R3 = H, A, C(:NH)NH2, solid phase; R4 = Ar, phenylalkyl, cycloalkyl, Het; Y = bond, C2-4 alkylene; A = (un)branched C1-6 alkyl; Ar = (un)substituted Ph, naphthyl, biphenyl, or benzofuranyl; Het = (un)substituted, (un)saturated mono- or bicyclic NOS heterocyclyl; Hal = F, Cl, Br, or iodo; n, m = 0-3].
The compds. are glycoprotein IbIX antagonists (no data), useful for treatment or prophylaxis of a variety of thrombotic disorders, or as anti-adhesive substances for implants, catheters, or heart pacemakers. For instance, an exemplary amine, [[3-(aminomethyl)cyclohexyl]methyl]amine, was supported on p-nitrophenyl carbonate resin, then coupled with various Fmoc-protected anthranilic acids. Cleavage of the Fmoc group, cyclocondensation with various aldehydes R4YCHO, oxidation of the resultant dihydroquinazolinone ring system, and cleavage from the resin with CF3CO2H, gave a variety of compds. I, e.g., the preferred compound II.
IT 332121-31-0P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-chloro-2-cyclohexyl-3H-quinazolin-4-one 332121-32-1P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methyl-2-cyclohexyl-3H-quinazolin-4-one 332121-33-2P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-7-chloro-2-cyclohexyl-3H-quinazolin-4-one 332121-34-3P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-6-methoxy-2-cyclohexyl-3H-quinazolin-4-one 332121-35-4P, 3-[[3-(Aminomethyl)cyclohexyl]methyl]-2-cyclohexyl-3H-quinazolin-4-one
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazolinone derivs. as glycoprotein IbIX

L4 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
antagonists)
RN 332121-31-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-6-chloro-2-cyclohexyl- (9CI) (CA INDEX NAME)



RN 332121-32-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-cyclohexyl-6-methyl- (9CI) (CA INDEX NAME)



RN 332121-33-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-7-chloro-2-cyclohexyl- (9CI) (CA INDEX NAME)



RN 332121-34-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-cyclohexyl-6-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 332121-35-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[3-(aminomethyl)cyclohexyl]methyl]-2-cyclohexyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:494627 CAPLUS
DOCUMENT NUMBER: 123:306582
TITLE: Angiotensin II receptor subtype 2 receptor (AT2) antagonists for inhibition of vascular restenosis, their preparation, and pharmaceutical compositions containing them
INVENTOR(S): Reilly, Christopher F.; DeLaszlo, Stephen E.; Johnson, Robert G.; Fujita, Tsuneo
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9503055	A1	19950202	WO 1994-US7837	19940713
W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5409926	A	19950425	US 1993-93833	19930719
AU 9473311	A1	19950220	AU 1994-73311	19940713
PRIORITY APPLN. INFO.:			US 1993-93833 A	19930719
			WO 1994-US7837 W	19940713

OTHER SOURCE(S): MARPAT 123:306582
GI



AB Disubstituted 6-aminoquinazolinones I [R1 = CO2R2 (R2 = H, C1-6 alkyl), tetrazol-5-yl; R4 = (substituted) C1-6 alkyl, C2-6 alkenyl, Ph C1-6 alkyl, heteroaryl C1-6 alkyl; R5 = CO2R7, COR8 (R7 = (substituted) C1-6 alkyl, Ph C1-6 alkyl, heteroaryl C1-6 alkyl; R8 = (substituted) C1-6 alkyl, Ph, heteroaryl, etc.); R6 = H, Me, Et, etc.; R9 = H, F, Cl, Br, I, C1-4 alkyl, C1-6 alkoxy; R10 = H, C1-5 alkyl, Ph] are useful as angiotensin II receptor (subtype 2) antagonists (AT2 antagonists) alone or in combination with heparin, and can act to suppress the vascular stenosis which commonly occurs during the development of atherosclerosis and the restenosis

L4 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
following arterial angioplasty, stent placement, bypass surgery, heart transplantation or endarterectomy. Prepn. of selected I is included. The effect of I (R1 = tetrazolyl; R4 = benzyl; R5 = CO-2-thiophene; R6 = Et; R9, R10 = H) (II) on restenosis in the rat was detd. Capsule, tablet, suppository, and injection formulations of II are presented.
IT 150484-45-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiotensin II receptor subtype 2 receptor antagonists for inhibition of vascular restenosis, their preparation, and pharmaceutical compns. containing them)
RN 150484-45-0 CAPLUS
CN Benzamide, N-[2-cyclopropyl-3,4-dihydro-4-oxo-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-6-quinazolinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:420519 CAPLUS
DOCUMENT NUMBER: 122:314564
TITLE: 6-Amino-3-(biphenylylmethyl)quinazolinones as angiotensin II antagonists
INVENTOR(S): De Laszlo, Stephen E.; Glinka, Tomasz W.; Greenlee, William J.; Chakravarty, Prasun K.; Patchett, Arthur A.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 37 pp. Cont. of U.S. Ser. No. 912,458, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5385894	A	19950131	US 1994-222354	19940404
PRIORITY APPLN. INFO.:			US 1994-222354	B1 19940404
			US 1992-912458	B2 19920713
			US 1991-665389	19910306

OTHER SOURCE(S): MARPAT 122:314564
GI



I

AB Novel disubstituted 6-aminoquinazolinones I (R4 = e.g., benzyl, Bu, Pr; R5 = e.g., CO2Bu-iso, CO2Me, CO2Pr; R6 = e.g., Bu, Pr) are useful as angiotensin II antagonists. In an antihypertensive screening, I exhibited an activity of IC50 < 50 mM, thereby demonstrating and confirming utility as AII antagonists. Pharmaceutical formulations were given.
IT 150484-44-9P 150484-45-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(6-amino-3-(biphenylylmethyl)quinazolinones as angiotensin II

L4 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
antagonists)
RN 150484-44-9 CAPLUS
CN Benzamide, N-[2-cyclopropyl-3,4-dihydro-4-oxo-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-6-quinazolinyl]-N-pentyl- (9CI) (CA INDEX NAME)



RN 150484-45-0 CAPLUS
CN Benzamide, N-[2-cyclopropyl-3,4-dihydro-4-oxo-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-6-quinazolinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:595691 CAPLUS
DOCUMENT NUMBER: 119:195691
TITLE: Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
INVENTOR(S): Chakravarty, Prasun K.; Naylor, E. M.; Ransom, Richard W.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 18 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5204354	A	19930420	US 1992-826726	19920214
PRIORITY APPLN. INFO.:			US 1992-826726	19920214

OTHER SOURCE(S): MARPAT 119:195691
AB Substituted quinazolinones (Markush shown) are useful for treating central nervous system (CNS) disorders, e.g. psychoses, depression, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependence, panic attack, and mania. The compds. had IC50 <50μM in a neurotensin binding assay using human frontal cortex.
IT 150484-44-9 150484-45-0
RL: BIOL (Biological study)
(as neurotensin antagonist, for treating central nervous system disorders)
RN 150484-44-9 CAPLUS
CN Benzamide, N-[2-cyclopropyl-3,4-dihydro-4-oxo-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-6-quinazolinyl]-N-pentyl- (9CI) (CA INDEX NAME)



RN 150484-45-0 CAPLUS
CN Benzamide, N-[2-cyclopropyl-3,4-dihydro-4-oxo-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-6-quinazolinyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:405315 CAPLUS
DOCUMENT NUMBER: 79:5315
TITLE: Isothiocyanates. 35. Amidino isothiocyanates. II. Isomerization, dimerization, and condensation reactions of amidino isothiocyanates
AUTHOR(S): Abraham, W.; Barnikow, G.
CORPORATE SOURCE: Sekt. Chem., Humboldt-Univ., Berlin, Ger. Dem. Rep.
SOURCE: Tetrahedron (1973), 29(5), 691-7
CODEN: TETRAB; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Isomerization of the title compds. p-RC6H4N:C(NR1R2)NCS (I, R = Cl, Br, NO2, R1 = R2 = Et, or NR1R2 = N heterocycle) in refluxing solvents gave the quinazolinethiones (II). I (NR1R2 = pyrrolidino) in Me2CO dimerized giving s-triazine derivs. by 1,4-1',2'-cycloaddn. Cycloaddn. of I (R = Br, NR1R2 = pyrrolidino) with PhNCO gave III. Similarly I and HSCN gave IV. Intermol. elimination of HSCN from I gave the amidinoquinazolines (V).
IT 49574-07-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 49574-07-4 CAPLUS
CN 4(3H)-Quinazolinethione, 7-bromo-3-[[(4-bromophenyl)imino]-1-pyrrolidinylmethyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:72047 CAPLUS
DOCUMENT NUMBER: 78:72047
TITLE: 3-Aryl-2-cyclopropyl-4(3H)-quinazolinones
AUTHOR(S): Somasekhara, S.; Dighe, V. S.; Gokhale, S. V.
CORPORATE SOURCE: Sarabhai Res. Cent., Baroda, India
SOURCE: Indian Journal of Pharmacy (1972), 34(5), 121-2
CODEN: IJPAAO; ISSN: 0019-5472
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB Twenty cyclopropylquinazolinones (I; R = Ph, o-MeC6H4, p-MeOC6H4, PhCH2, etc.; R1 = H, Cl) were prepared by condensing o-aminobenzanilide derivs. with cyclopropanecarboxylic acid or N-cyclopropylcarbonylanthranilic acid with aromatic amines, in pyridine with PCl3. At 100 mg/kg I (R = o-MeC6H4) produced hypoactivity and ataxia in mice. The ED50 of I (R = m-MeOC6H4) against electroshock convulsions in mice was 75 mg/kg.
IT 40057-10-1P 40057-11-2P 40057-18-9P
40057-19-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 40057-10-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-cyclopropyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 40057-11-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-cyclopropyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 40057-18-9 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-2-cyclopropyl-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 40057-19-0 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-2-cyclopropyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)